Maridebart Cafraglutide
NCT05669599
Amgen · Phase 2 · Completed · Enrollment 592
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Cohort A: Maridebart Cafraglutide | n/r | n/r | n/r | n/r |
| Cohort A: Placebo | n/r | n/r | n/r | n/r |
| Cohort B: Maridebart Cafraglutide | n/r | n/r | n/r | n/r |
| Cohort B: Placebo | n/r | n/r | n/r | n/r |
Not shown
- Cohort A: Maridebart Cafraglutide: endpoint not reported
- Cohort A: Placebo: endpoint not reported
- Cohort B: Maridebart Cafraglutide: endpoint not reported
- Cohort B: Placebo: endpoint not reported